Alzprotect, a french biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, today announced that PAREXEL Biotech, a new division of PAREXEL International Corporation, has been selected to perform the clinical phase 2a development of the drug candidate AZP2006 for the treatment of progressive supranuclear palsy, a rare degenerative disease of the brain. PAREXEL Biotech will fulfill AlzProtect’s needs related to the completion of their Phase 2a clinical study from protocol writing to the coordination of patient recruitment.
“It was important for us to work with an internationally renowned partner covering the full range of needs for our first phase 2a clinical trial,” said Philippe Verwaerde, president and scientific director of AlzProtect.
“AlzProtect is committed to achieving Phase 2a results in complete confidence. With PAREXEL Biotech, we now have access to the expertise necessary to achieve this goal,” said Laurent Dupire COO of AlzProtect.
“PAREXEL’s recently launched Biotech unit delivers innovative, customized offerings to the biotech community, building on our more than 20 years of experience in this area,” said Jim Anthony, Global Head of Biotech, PAREXEL. “Our collaboration with AlzProtect is a great example of how we can work together in a unique way, and we look forward to helping advance this important rare disease initiative.”